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While a variety of therapeutic options continue to emerge for 
COVID-19 treatment, convalescent plasma (CP) has been used 
as a possible treatment option early in the pandemic. One 
of the most significant challenges with CP therapy, however, 
both when defining its efficacy and implementing its approach 
clinically, is accurately and efficiently characterizing an otherwise 
heterogenous therapeutic treatment. Given current limitations, 
our goal is to leverage a SARS antibody testing platform with 
a newly developed automated endpoint titer analysis program 
to rapidly define SARS-CoV-2 antibody levels in CP donors and 
hospitalized patients. A newly developed antibody detection 
platform was used to perform a serial dilution enzyme-linked 
immunosorbent assay (ELISA) for immunoglobulin (Ig)G, IgM, 
and IgA SARS-CoV-2 antibodies. Data were then analyzed using 
commercially available software, GraphPad Prism, or a newly 
developed program developed in Python called TiterScape, to 
analyze endpoint titers. Endpoint titer calculations and analysis 
times were then compared between the two analysis approaches. 
Serial dilution analysis of SARS-CoV-2 antibody levels revealed 
a high level of heterogeneity between individuals. Commercial 
platform analysis required significant time for manual data input 
and extrapolated endpoint titer values when the last serial dilution 
was above the endpoint cutoff, occasionally producing erroneously 
high results. By contrast, TiterScape processed 1008 samples for 
endpoint titer results in roughly 14 minutes compared with the 
8 hours required for the commercial software program analysis. 
Equally important, results generated by TiterScape and Prism 
were highly similar, with differences averaging 1.26 ± 0.2 percent 
(mean ± SD). The pandemic has created unprecedented challenges 
when seeking to accurately test large numbers of individuals 
for SARS-CoV-2 antibody levels with a rapid turnaround time. 
ELISA platforms capable of serial dilution analysis coupled with 
a highly flexible software interface may provide a useful tool when 
seeking to define endpoint titers in a high-throughput manner. 
Immunohematology 2021;37:33–43.
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The coronavirus disease 2019 (COVID-19) pandemic 
continues to cause significant morbidity and mortality, 
place unprecedented challenges on health care systems, and 
affect the global economy. Early efforts to diagnose and treat 
COVID-19 largely relied on nucleic acid testing and basic 
supportive care. Among treatment options considered early 
in the pandemic, convalescent plasma (CP) therapy quickly 
emerged as a potential strategy to combat the new SARS-
CoV-2 pathogen.1 Despite conflicting data regarding its efficacy, 
the goal of CP therapy is to provide plasma harvested from 
a COVID-19–recovered donor that contains SARS-CoV-2 
antibodies.2,3 In doing so, this approach is designed to leverage 
the immune response of a recovered individual to enhance viral 
clearance in a patient with active COVID-19. Nevertheless, 
variability in the antibody response to infectious organisms 
in general, and SARS-CoV-2 in particular, among potential 
CP donors can make it difficult to establish the effectiveness 
of this approach. Early in the pandemic, limitations in 
serologic testing availability prevented nearly all CP units 
collected from being tested for SARS-CoV-2 antibodies before 
transfusion.1,4,5 Even when serologic testing became available, 
most testing platforms were validated to decipher the presence 
or absence of SARS-CoV-2 antibodies, but not necessarily the 
antibody titers. While raw values produced by existing testing 
strategies may be used to infer SARS-CoV-2 antibody titers, 
few of these approaches are validated to accurately measure 
antibody titers. Because recent studies have suggested that 
SARS-CoV-2 antibody levels in CP units may affect efficacy, 
overcoming current limitations in the assessment of SARS-
CoV-2 antibody levels would be predicted to greatly facilitate 
the overall efficacy of this therapeutic approach.6,7
A variety of strategies have been implemented to 
determine SARS-CoV-2 antibody levels.8 All of these strategies 
use some components of the virus as a target antigen. The 
spike in glycoprotein of SARS-CoV-2, responsible for viral 
entry, has been the most common target antigen used in 
these assays. However, other SARS-CoV-2 antigens, such as 
the nucleoprotein, have also been used.9 Additional platforms 
have relied on a specific portion of the spike protein called 
the receptor-binding domain (RBD), so-called because of 
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its critical role in mediating direct interactions with the 
ACE2 receptor on host cells.10–13 Recent results suggest that 
SARS-CoV-2 antibodies directed against the RBD correlate 
with neutralizing antibody levels, demonstrating that anti-
RBD levels may provide a useful surrogate for SARS-CoV-2 
antibody activity.14 This finding is especially important when 
considering that, although neutralizing assays are often 
considered the gold standard for assessing antiviral antibody 
activity, these approaches can be difficult to establish as 
high-throughput tests, making it difficult to implement this 
approach clinically.15 Using an enzyme-linked immunosorbent 
assay (ELISA) approach with a key antigen as a surrogate 
for functional assays also allows direct examination of the 
antibody isotype, a feature of antibodies that dictates antibody 
localization and therefore a function not typically assessed 
in neutralization assays. This feature is especially important 
when considering that, while most assays examine total or 
immunoglobulin (Ig)G-specific antibody levels against SARS-
CoV-2, few examine IgA, the isotype with the unique ability to 
be translocated to the respiratory mucosa where the virus is 
believed to predominately replicate.16
Once a serologic assay is developed, endpoint titer 
calculations are often used to provide an accurate assessment 
of antibody levels. This approach requires serial dilutions and 
ultimately approximates the level of a given antibody in serum 
or plasma. To optimize endpoint titer calculations, while also 
generating data that allow reproducible results, mathematical 
approaches are most commonly used to derive endpoint 
titers after serial dilution ELISA approaches. Three common 
methods used to calculate endpoint titers are the Reed and 
Muench method, Spearman-Karber method, and t statistic.17–19 
To calculate and analyze endpoint titers conveniently, most 
researchers use a commercial data analysis program called 
Prism because it incorporates these mathematical and 
statistical methods.20–25 Although platforms like Prism are 
useful, they are not designed to handle a large number of 
tests in clinical assays. Furthermore, without an interface 
to automatically connect output data from an analyzer to an 
analysis software, raw data transfer is subject to transcribing 
errors common in laboratory practice.26
To increase the efficiency of data analysis and reduce 
human errors, we developed a data analyzing program, 
TiterScape, and coupled it with an automated endpoint titer 
assay to streamline the process of endpoint titer analysis. 
Using this approach, the time required to analyze 1000 samples 
for endpoint titer results was reduced by 98 percent, from 8 
hours to 14 minutes. Together with the RBD target antigen, 
our newly developed program could enable donor centers and 
hospitals to establish antibody isotype-specific endpoint titers 
efficiently, directly aiding in providing the best possible match 
for CP therapy.
Materials and Methods
Sample Collection and Processing
A total of 1008 samples was used to test TiterScape’s 
performance. The samples were a combination of samples 
from CP donors and hospitalized patients with varying 
COVID-19 severity, collected from residual serum or plasma 
samples at Emory University Hospital and Emory University 
Hospital Midtown from 3 March 2020 to 15 May 2020. 
Symptom onset was established by chart review by at least 
two independent physicians. Sample collection and chart 
review were performed in accordance with Emory University 
institutional review board approval.
RBD-Based ELISA
The RBD was purified using a 6x His tag, as previously 
described.10,12 The purified RBD was then coated on the high-
bind ELISA plates at a concentration of 1 µg/mL in phosphate-
buffered saline (PBS) overnight at 4°C or at 37°C for 1 hour. 
Plates were washed three times with 0.5 percent bovine serum 
albumin (BSA) and 0.2 percent Tween 20 in PBS solution 
and blocked for 30 minutes at room temperature in buffer 
containing the same 0.5 percent BSA and 0.2 percent Tween 
20 in PBS solution. Plates were then incubated with plasma 
samples pre-diluted at 1:150, 1:450, and so on (by a factor 
of 3) at room temperature for 30 minutes and then washed 
with 0.5 percent BSA and 0.2 percent Tween 20 in PBS. The 
following anti-human preparations, IgG (Goat Anti-Human 
IgG, Catalog #62-8420; Invitrogen, Carlsbad, CA), IgA (Goat 
Anti-Human IgA-HRP, Catalog #2050-05; Southern Biotech, 
Birmingham, AL), and IgM (Goat Anti-Human IgM, HRP, 
Catalog #31415; Invitrogen) were used for detection. The 
substrate (SigmaFAST OPD; Sigma-Aldrich, St. Louis, MO) 
was used for development per the manufacturer’s instructions, 
and reactions were stopped using 1N HCl before reading on 
a plate reader (Synergy; BioTek; Winooski, VT) for optical 
density (OD) at 492 nm.14
Programming Method
TiterScape was written in a general-purpose and high-
level programming language (Python; Python Software 
Foundation, Wilmington, DE).27 The program parsed through 
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all the spreadsheet files (Excel; Microsoft, Redmond, WA) 
files in the designated directory once to make sure all input 
COVID sample files were in the correct format. Each input file 
had a total of 24 samples, and each sample had three antibodies 
(IgG, IgM, and IgA) with eight dilutions. The program can 
process any number of files given that the information is 
within the capacity of the computer memory. The program 
combined all input files and determined endpoint titers (in 
both logarithmic and decimal form) for each sample’s SARS-
CoV-2 antibodies. A sample’s antibody concentration was 
plotted against its OD value and fitted to a sigmoidal curve. 
The endpoint titer was then calculated by taking the given 
cutoff OD value and finding its corresponding concentration 
on the sigmoidal curve. If the cutoff OD value was higher than 
the maximum value of the data set, the program would return 
a zero to indicate no concentration was detected. In contrast, 
the program would extrapolate a value if the cutoff was below 
the minimum value. At the end of program execution, a 
spreadsheet file (Excel; Microsoft) of the samples’ calculated 
endpoint titers and their corresponding graphs was available. 
This output process was used to generate all laboratory values.
Comparison of TiterScape and Prism Outputs
R2 values were determined by entering endpoint titers 
produced by Prism or TiterScape into Prism for comparison. 
A Student t test was used to directly compare titer outputs 
generated by both programs.
Results
To facilitate the detection of SARS-CoV-2 antibody 
endpoint titers, we first generated raw OD data by ELISA 
analysis over a series of eight dilutions. We then analyzed these 
data using Prism for endpoint titers to provide a comparator 
for a new program capable of directly interfacing with data 
output (Fig. 1A). This approach required the transfer of raw 
output data to a spreadsheet file (Excel; Microsoft), followed 
by reformatting and manual input into the Prism software 
database. This process allows a maximum of 256 samples to 
be analyzed in a given setting, with an average data transfer 
and input time of 2 minutes per sample. Although this 
approach is widely used, the time limitations associated with 
Prism software analysis, coupled with the possibility for error 
in manual data transfer, made this approach a major limitation 
in the use of the automated ELISA platform. To substantially 
reduce the time required for endpoint titer analysis, we 
pursued possible programming alternatives that may directly 
facilitate this last, but important, step in the evaluation of 
SARS-CoV-2 antibody levels (Fig. 1B). To this end, we used 
an open-source programming platform, Python 3 (Python 
Software Foundation), which offers the greatest flexibility in 
data structure and runtime complexity.27 Using this approach, 
data output in the form of raw OD values in the designated 
folder are processed and analyzed automatically. This program 
was designed to use the same mathematical and statistical 
approach used by the Reed and Muench method, the most 
commonly used algorithm for endpoint titer calculations.17–19 
The output of the program results in curve-fitting graphs for 
each antibody isotype, a negative log value, and the actual 
endpoint titer.
To compare the results of Prism and TiterScape directly, 
we first examined the fitted curves generated by these two 
programs. The curve fitting ultimately dictates the endpoint 
titer cutoff when using this mathematical approach. As shown 
in the plots generated from a randomly selected set of data, 
both programs produced similar curve fits for data generated. 
Such similarities were observed when comparing individuals 
with distinct serologic responses. For example, for an 
individual with high IgG concentration and lower IgA and IgM 
concentrations (IgA being the lowest), the IgG fitting showed 
an inverted logistic curve, whereas IgA and IgM fittings had 
inverted exponential functions (Fig. 1C). In contrast, curves 
generated for an individual with high IgM concentration 
and lower IgG and IgA concentrations were also similar, 
with all three fittings inverted exponentially with similar 
slopes (Fig. 1D). Each program also provided similar fitting 
approaches for an individual with high IgA concentration and 
lower IgG and IgM concentrations, where all three fittings 
were inverted logistically with similar slopes (Fig. 1E and F). 
These examples suggest that each software program produces 
similar overall curve-fitting data.
Although the sigmoidal curves of both programs looked 
similar, endpoint titer values are the numbers within this 
approach that would be predicted to be most useful when 
making decisions regarding the possible utility of a CP donor. 
As a result, we directly compared the endpoint titer values 
obtained from the output of each program. The endpoint titers 
of each program were plotted categorically and linked with a 
straight line, with most values showing significant similarity 
because the connected lines were parallel (Fig. 2A). As a 
complementary approach, endpoint titers generated by each 
program were directly compared against each other and fitted 
with a line of best fit (linear function) with the R2 values on 
the side (Fig. 2B). The R2 values for IgG, IgM, and IgA are 
36 IMMUNOHEMATOLOGY, Volume 37, Number 1, 2021
A.D. Ho et al.
Fig. 1 TiterScape analysis for determining SARS-CoV-2 antibody levels. (A) Before having an automatic data-processing program, the user 
has to manually input data one file at a time and copy and paste the desired input into Prism and then use Prism to obtain endpoint titers. 
(B) Once TiterScape is executed in the terminal, all optical density (OD) file inputs in the designated folder will be processed and analyzed 
automatically. (C–F) Different patient curve fits produced by Prism or TiterScape. The graphs shown were either produced by Prism (left) or 
Titerscape (right) as indicated. DF = dilution factor.
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0.9969, 0.9975, and 0.9925, respectively, which suggest a 
strong similarity between the two programs. These results 
suggest that the two programs produce comparable endpoint 
titer results.
In addition to evaluating CP, it was suggested that 
determining SARS-CoV-2 antibody levels in patients may 
be useful in seeking to determine which patients may most 
likely benefit from this intervention.28–30 Patients who already 
possess high SARS-CoV-2 antibody titers may not benefit 
from this type of intervention as much as people with reduced 
antibody levels.28–30 Being able to determine antibody levels 
before transfusion would therefore be predicted to facilitate the 
efficient distribution of this limited resource.31 To evaluate each 
analysis software performance on endpoint titer calculations 
for patients, we examined endpoint titer values over time after 
symptom onset using both approaches (Fig. 3). Using this 
Determination of ELISA endpoint titers
Fig. 2 Comparison of TiterScape and Prism. (A) Analysis of each program’s accuracy separated by immunoglobulin (Ig)G, IgM, and IgA. The 
p values for IgG, IgM, and IgA are 0.39, 0.38, and 0.33, respectively. (B) Endpoint titer outputs produced by TiterScape and Prism separated 
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strategy, data output from the two programs largely agree with 
each other, with the most significant variation occurring at the 
highest endpoint titer levels (Fig. 3).
To see if this endpoint analysis software accomplishes our 
goal of reducing the time needed to obtain endpoint results 
after initial OD value production, we next compared the 
analysis time required for these two platforms. To accomplish 
this, we ran multiple trials to compare the execution time 
between programs with various amounts of samples (up to 
1008 samples) (Fig. 4). A data table was presented to show 
the time each program needed to process a given number of 
samples (Fig. 4A). As indicated in the graph, both approaches 
generated a linear runtime (Fig. 4B). For 24 samples, the 
execution times of TiterScape and the Prism approach are 
Fig. 3 Examination of patient antibody (Ab) endpoint titers produced by TiterScape or Prism at each day after symptom onset (SO). (A) 
Endpoint titer results generated by TiterScape for immunoglobulin (Ig)G , IgM, and IgA SARS-CoV-2 antibodies. (B) Endpoint titer results 
generated by Prism for IgG, IgM, and IgA SARS-CoV-2 antibodies.
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0.29 and 11.43 minutes, respectively. When the sample size 
increased to 1008, TiterScape took 14.98 minutes to complete 
the task, while the manual Prism approach took more than 
480 minutes (8 hours). Taken together, these results suggest 
that TiterScape-mediated analysis can greatly reduce the time 
required for endpoint titer analysis.
Discussion
Whereas raw OD values may provide important informa-
tion when seeking to establish SARS-CoV-2 antibody levels in 
a potential donor, endpoint titer analysis provides an important 
measure when seeking to determine the overall suitability of a 
given donor for CP. The utility of titer analysis is not unique 
to CP, but also occurs in other settings where antibody levels 
can directly affect clinical decisions. Measurement of factor 
VIII antibody activity in patients with hemophilia A through 
a titering process, for example, directly influences the type of 
therapeutic intervention that will likely be the most beneficial 
in patients who develop factor VIII antibodies.32,33 ABO(H) 
antibody titers also dictate whether ABO(H) incompatible 
transplantation can occur.34,35 Because delivering SARS-
CoV-2 antibodies is the primary purpose of CP therapy, 
accurate assessment of antibody levels would be predicted to 
aid in the identification of units that would be most beneficial 
for a given patient.36 However, because titer processes often 
require considerable time, approaches that reduce turnaround 
times are needed.37,38 The ability of TiterScape to rapidly 
calculate titer values from raw data offers significant promise 
in facilitating the delivery of SARS-CoV-2 antibody titer results 
in a clinically relevant time frame.
Characterizing antibody levels in convalescent plasma 
units is critical when establishing the dose of SARS-CoV-2 
antibodies in a given unit, but defining SARS-CoV-2 antibody 
levels in patients may also be beneficial when seeking to 
optimally manage the use of this therapy.28–30 Recent data 
suggest that CP with higher titer SARS-CoV-2 antibodies 
administered early in COVID-19 provides the most benefit to 
patients.6,7,39,40 The possible efficacy of CP early in COVID-19 
disease progression may reflect a variety of distinct COVID-19 
characteristics. However, the lack of an early antibody 
response in most patients is consistent with a relative deficit 
in the humoral immunity toward SARS-CoV-2 shortly after 
symptom onset, when CP appears to be most beneficial.41 
In contrast, studies demonstrate that patients with severe 
COVID-19 often possess high levels of SARS-CoV-2 antibodies, 
strongly suggesting that disease manifestations at these 
later times may not reflect an inadequate humoral immune 
response, possibly explaining the lack of CP efficacy in this 
patient population.14,29,30,41,42 Patients with severe COVID-19 
appear to benefit instead from immunosuppressive therapy 
with dexamethasone, suggesting that later disease stages may 
not result from an inadequate immune response, but may 
instead be driven by an exuberant inflammatory response, 
occasionally accompanied by autoimmune signatures, as 
opposed to active viral replication.43–46 Because the overall 
kinetics and magnitude of an immune response to SARS-
CoV-2 can differ between patients, however, assessing whether 
a given patient is actually experiencing a relative deficiency 
in SARS-CoV-2 antibody levels before initiating CP therapy 
may directly aid in determining whether a patient could 
theoretically benefit from this therapy.29,30,41 Such an approach 
is not uncommon in transfusion medicine. The vast majority 
Fig. 4 Execution time comparison of TiterScape and Prism. (A) 
TiterScape has a linear runtime that can process and analyze 
1008 samples in less than 15 minutes. (B) Manual data input and 
processing requires at least 8 hours to similarly process and analyze 





TiterScape runtime  
(minutes)
Estimated manual input time 
(minutes)
1 24 0.29 11.43
2 48 0.57 22.86
3 72 0.84 34.29
4 96 1.26 45.71
5 120 1.59 57.14
10 240 3.70 114.29
15 360 5.20 171.43
20 480 7.79 228.57
30 720 10.42 342.86
40 960 13.74 457.14
42 1008 14.98 480.00
A
B
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of transfusion decisions are influenced by a combination of 
laboratory values, such as hemoglobin levels, platelet counts, or 
clotting activity, in addition to the clinical status of the patient, 
when determining whether a particular blood component is 
warranted.47–49 Even more tailored transfusion therapy, such 
as red blood cell or platelet phenotype matching protocols, 
likewise rely on evaluation of key features of the patient before 
optimal transfusion management can be achieved.50–53 These 
precedents, coupled with recent data suggesting that early 
administration in general may be optimal, raise the possibility 
that a similar assessment of a patient’s SARS-CoV-2 antibody 
levels, including individual antibody isotypes, may allow for 
a more tailored CP therapy approach to be used.6,7,29,39,40,54 In 
doing so, this approach may allow a more targeted overall 
strategy while providing CP, which is often in limited supply, 
primarily for patients who are deficient in SARS-CoV-2 
antibodies and therefore predicted to most likely benefit from 
this approach.
To provide a more patient-centered approach to CP 
therapy, accurate and timely assessment of donor and patient 
antibody levels is needed. The development of a physical 
testing infrastructure often receives the most immediate 
attention when seeking to implement new serologic testing 
approaches.55 Indeed, at our institution, the initial development 
of an RBD-based ELISA was fueled by the perceived need 
to rapidly assess both patients and CP donors for SARS-
CoV-2 antibodies. The RBD was chosen as a target antigen 
based on its functional role in binding to ACE2 and recent 
data suggesting that antibodies directed against the RBD 
may provide a useful surrogate when seeking to establish an 
ELISA-based approach that may correlate with neutralizing 
titer activity.14 Most serologic approaches, including the initial 
implementation of our assay, used a simple one-dilution assay 
for antibody measurement.56,57 This strategy can be useful 
and was designed to rapidly assess the presence or absence 
of SARS-CoV-2 antibodies in a timely manner for diagnostic 
and epidemiologic purposes.8 Such an approach can even be 
coupled with a pooling strategy to expand the throughput of 
serologic screening strategies.13 However, OD values alone are 
limited in their ability to provide accurate measurements of 
antigen-specific antibody levels. The development of a serial 
dilution assay based on an ELISA approach was designed 
to provide raw OD values that could then be extrapolated 
to calculate endpoint titers.17–19 In this way, CP units could 
be identified that would be predicted to fill specific defects 
observed in a patient’s humoral immune response.
While the implementation of an automated testing 
infrastructure can generate OD values in a high-throughput 
manner, commercially available software can become a 
limitation in providing actual endpoint titer results. Software 
packages such as Prism are useful in calculating endpoint 
titers. However, most commercial software platforms are 
understandably not designed for high-throughput data 
analyses. Furthermore, these platforms do not possess 
the needed interface capable of automatically linking raw 
instrument data output with an analytical approach. Instead, 
these platforms require individuals to manually input data, 
which often necessitates data reformatting before Prism's 
analysis and increases the chance for human error. In 
addition, limitations often exist in the numbers of analyses 
that can be performed at a given time. For example, Prism 
can only process 256 entries in one setting. Another limitation 
not entirely foreseen when designing and then comparing 
TiterScape with Prism was the intrinsic propensity of Prism 
to extrapolate endpoint titers when cutoff values were out of 
the data range. In these scenarios, extrapolating below the 
minimum value of a data set is reasonable, since the estimate 
already indicates a low antibody concentration. Extrapolating 
above the maximum value of a data set may be misleading, 
however, because the estimate is out of the detection limit 
of OD, often producing an erroneously higher titer value 
than may actually be present. However, because an accurate 
measurement of antibody levels at the extremes (very high 
or very low antibody levels) is not likely to be clinically 
meaningful, the consequences of this information on CP donor 
identification and patient characterization are likely minimal. 
Similar to Prism, TiterScape calculates the endpoint titer by 
fitting data with a sigmoidal function. Use of a sigmoidal 
function aids in balancing outliers, especially the values located 
at the extremities. This approach produced similar overall 
results as obtained using the Prism software. In our runtime 
testing trials, both approaches behaved linearly. In the manual 
approach simulation, however, we could only test and record 
up to 48 samples; the rest of the data were a linear estimate 
based on the first two trials. In reality, any manual approaches 
should behave exponentially as the workload increases due to 
natural variations in work efficiency as individuals responsible 
for manual data input fatigue. These limitations in no way 
suggest that Prism and comparable commercial analysis 
software packages are not useful. Instead, these data simply 
suggest that many platforms may not be optimally suited 
for clinical use, which is what motivated the development of 
TiterScape.
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Challenges with collecting and characterizing CP for use 
in the ongoing COVID-19 pandemic continue to limit the 
full implementation of this approach. U.S. Food and Drug 
Administration guidance regarding optimal titers and quality 
control measures has evolved. However, regardless of the 
current recommendations, efficient and accurate methods 
to assess SARS-CoV-2 antibody levels are needed to fully 
implement this approach. After comparing the performance 
and outputs of TiterScape and Prism, we think these data 
suggest that the use of TiterScape offers a more convenient and 
efficient way to calculate endpoint titers, while maintaining 
accuracy. Designing assays that provide a useful surrogate 
for neutralizing antibody levels coupled with evaluation of 
antibody isotype may provide a pragmatic balance between 
functional neutralizing titer approach and timely result output 
that could directly facilitate the use of this therapy. As a result, 
coupling the ELISA approach with a software interface such as 
TiterScape could greatly facilitate the measurement of SARS-
CoV-2 antibody levels in a potential CP donor or patient with 
COVID-19 and therefore provide the best possible match 
when considering this therapeutic approach. Efforts to expand 
this program to integrate with multiple interfaces, including 
the Blood Establishment Computer System, are underway. In 
summary, we think that this or similar overall strategies may 
be beneficial for analyzing large numbers of samples and, in so 
doing, directly facilitate the optimal matching of CP units with 
COVID-19 patients.
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